{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:41:20Z","timestamp":1769074880807,"version":"3.49.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.critrevonc.2016.05.009","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T14:46:25Z","timestamp":1463237185000},"page":"99-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question"],"prefix":"10.1016","volume":"103","author":[{"given":"Kendra","family":"Sweet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2016.05.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2771.2771","article-title":"Effect of nilotinib (NIL) on molecular response in chronic myelogenous leukemia \u2013 chronic phase (CML-CP) patients (pts) with a suboptimal molecular response to imatinib (IM)\u2014ENABL study update","author":"Ailawadhi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0010","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0015","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0020","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0030","series-title":"Bosulif (bosutinib) [Package Insert]","year":"2013"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0040","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0045","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and>10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0055","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ajh.23501","article-title":"Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients","volume":"88","author":"Cerrano","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0060","first-page":"100","article-title":"Efficacy of nilotinib vs high-dose imatinib vs sustaining standard-dose imatinib in early chronic phase CML patients who have suboptimal molecular response to frontline imatinib","author":"Choi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0065","first-page":"120","article-title":"Change in chronic low-grade nonhematologic adverse events (AEs) and quality of life (QoL) in adult patients (pts) with Philadelphia chromosome-positive (Ph +) chronic myeloid leukemia in chronic phase (CML-CP) switched from imatinib (IM) to nilotinib (NIL)","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.clml.2013.12.002","article-title":"Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis","volume":"14","author":"Deangelo","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0075","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0080","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0085","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0090","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.leukres.2013.07.003","article-title":"Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors","volume":"38","author":"Efficace","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0095","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3324\/haematol.2013.095158","article-title":"Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib frontline therapy","volume":"99","author":"Etienne","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0100","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0105","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0110","doi-asserted-by":"crossref","first-page":"E206","DOI":"10.1002\/ajh.23816","article-title":"Do chronic myeloid leukemia patients with late \"warning\" responses benefit from \"watch and wait\" or switching therapy to a second generation tyrosine kinase inhibitor?","volume":"89","author":"Garc\u00eda-Guti\u00e9rrez","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0120","series-title":"Gleevec (imatinib) [Package Insert]","year":"2015"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0125","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","article-title":"Impact of low-grade averse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"30","author":"Gu\u00e9rin","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0130","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0135","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0140","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0145","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3324\/haematol.2013.091272","article-title":"Safety and efficacy of switching to nilotinib 400mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300mg twice daily","volume":"99","author":"Hughes","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0150","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","article-title":"Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib","volume":"124","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0155","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0160","first-page":"100","article-title":"ENESTcmr 4-year results: patients with chronic myeloid leukemia in chronic phase and resisdual disease more likely to achieve deep molecular response following switch to nilotinib","author":"Hughes","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0165","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0170","series-title":"Iclusig (ponatinib) [Package Insert]","year":"2015"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0175","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0180","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0185","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0190","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ajh.23707","article-title":"BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase","volume":"89","author":"Kim","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0195","first-page":"126","article-title":"Dasatinib in patients with chronic phase chronic meloid leukemia with persistent, low-grade nonhematologic toxicity to imatinib: results from Dasperse (CA180-400)","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0200","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0205","first-page":"99","article-title":"Ponatinib in patients (pts) with philadelphia chromosome\u2013positive (ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow-up of the PACE trial","author":"le Coutre","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0210","first-page":"100","article-title":"Final LASOR results: switch to nilotinib in patients with chronic myeloid leukemia in chronic phase and suboptimal cytogenetic response to frontline imatinib","author":"le Coutre","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0215","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: the new goal of therapy","volume":"20","author":"Mahon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0220","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0225","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0230","first-page":"122","article-title":"Long term follow-up after imatinib cessation for patients in deep molecular response: the update results of the STIM1 study","author":"Mahon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0235","first-page":"122","article-title":"Preliminary report of the STIM2 study: a multicenter Stop Imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib","author":"Mahon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0240","first-page":"32","article-title":"Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath","author":"Mahon","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0245","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0250","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0255","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0265","series-title":"NCCN Clinical Practice Guidelines in Oncology","author":"NCCN","year":"2016"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0270","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0275","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0280","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0285","first-page":"126","article-title":"ENESTpath: a phase III study to assess the effect of nilotinib treatment duration on treatment-free remission in chronic-phase chronic myeloid leukemia patients previously treated with imatinib: interim analysis from the first year of induction phase","author":"Rea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0290","first-page":"126","article-title":"Rapid achievement of MR4.5 after switching from imatinib (IM) to nilotinib (NIL) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP): preliminary results from ENESTgoal","author":"Ritchie","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0295","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0300","first-page":"99","article-title":"First interim analysis of a pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial","author":"Saussele","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0305","doi-asserted-by":"crossref","first-page":"457","DOI":"10.18553\/jmcp.2012.18.6.457","article-title":"Application of decision-analytic models in personalized medicine for CML treatment decisions made by payers, providers, and patients","volume":"18","author":"Saverno","year":"2012","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0310","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0315","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0320","series-title":"Sprycel (dasatinib) [Package Insert]","year":"2015"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0325","first-page":"124","article-title":"Final results from SENSOR: switch to nilotinib after molecular suboptimal response (SoR) to frontline imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP)","author":"Tanimoto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0330","series-title":"Tasigna (nilotinib) [Package Insert]","year":"2015"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0335","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0340","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"Wu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0345","first-page":"99","article-title":"SENSOR interim data with mutation analysis: switching to nilotinib after molecular suboptimal response to imatinib in patients with chronic myeloid leukemia in chronic phase","author":"Yamamoto","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0350","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.05.009_bib0355","doi-asserted-by":"crossref","DOI":"10.1179\/1607845415Y.0000000034","article-title":"Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib","author":"Yue","year":"2015","journal-title":"Hematology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T23:17:22Z","timestamp":1655939842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":71,"alternative-id":["S1040842816301160"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.05.009","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}